Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.
The American College of Physicians statement outlines how the “status quo” created health inequalities and prevented the spread of the COVID-19 virus, and outlines steps on how to move forward.
From an ethical perspective, disclosing adverse events to patients is predicated on the idea that physicians have obligations to tell the truth, but physicians may worry that apologizing will incur greater responsibility for liability.
In an effort to aid real-time epidemiology efforts, researchers have unveiled a mobile application called the COVID Symptom Tracker.
The American Hospital Association survey provided data to determine the availability of telemedicine services at US hospitals in 2019.
The use of telemedicine has been surging since the onset of coronavirus disease 2019 (COVID-19), with millions of Americans now using this medium for connecting with their clinicians.
Researchers found that the drug regimens were associated with an increased risk of death even after accounting for factors such as age, race, BMI, and comorbidities.
It is certainly too early to know if there will be any seasonal variation to SARS-CoV-2 infection, and there is no reason to specifically compare this virus with the seasonal behavior of influenza virus or to other seasonal respiratory viruses.
The phase 2b trial is expected to include roughly 2000 participants with confirmed SARS-CoV-2 who are experiencing fever, cough, and/or shortness of breath.
In light of the COVID-19 pandemic, Psychiatry Advisor is making an effort to speak with providers from all professional backgrounds to gain insight into the field’s response to the current crisis.
